CompletedPHASE1, PHASE2NCT00089037

Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

Studying Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Fred Hutchinson Cancer Center
Principal Investigator
Hans-Peter Kiem, MD, PA-C
Fred Hutchinson Cancer Center
Intervention
methotrexate(drug)
Eligibility
All sexes
Timeline
20032005

Study locations (1)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00089037 on ClinicalTrials.gov

Other trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Additional recruiting or active studies for the same condition.

See all trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

← Back to all trials